Cost of Revenue: Key Insights for Jazz Pharmaceuticals plc and CRISPR Therapeutics AG

Biotech Giants' Cost Trends: Jazz vs. CRISPR

__timestampCRISPR Therapeutics AGJazz Pharmaceuticals plc
Wednesday, January 1, 20141513000117418000
Thursday, January 1, 201512573000102526000
Friday, January 1, 201642238000105386000
Sunday, January 1, 201769800000110188000
Monday, January 1, 2018113773000121544000
Tuesday, January 1, 2019179362000127930000
Wednesday, January 1, 2020269407000148917000
Friday, January 1, 202117953000440760000
Saturday, January 1, 2022110250000540517000
Sunday, January 1, 2023130250000435577000
Monday, January 1, 2024-2314000
Loading chart...

Unveiling the hidden dimensions of data

Cost of Revenue Trends: Jazz Pharmaceuticals vs. CRISPR Therapeutics

In the evolving landscape of biotechnology and pharmaceuticals, understanding cost structures is crucial. Jazz Pharmaceuticals plc and CRISPR Therapeutics AG, two industry leaders, have shown distinct trends in their cost of revenue from 2014 to 2023. Jazz Pharmaceuticals, with a consistent upward trajectory, peaked in 2022 with a cost of revenue approximately 4.6 times higher than its 2014 figure. This reflects their expanding operations and product portfolio. In contrast, CRISPR Therapeutics AG, a pioneer in gene editing, experienced a more volatile pattern. Their cost of revenue surged by over 17,000% from 2014 to 2020, highlighting rapid growth and investment in cutting-edge technologies. However, a notable dip in 2021 suggests strategic adjustments or operational efficiencies. These insights underscore the dynamic nature of the biotech sector, where innovation and cost management are key to sustaining growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025